Mercedes-backed ProLogium starts 381 Wh/kg solid-state production as carmakers watch from sidelines

Mercedes-Benz and ProLogium have signed a joint testing agreement for ProLogium's Gen4 solid-state battery cells, building on a decade-long partnership. The agreement grants Mercedes-Benz priority access to test the technology, which offers high energy density, safety, and performance. ProLogium plans to go public on NASDAQ in 4Q2026 under the ticker PRLG.

ProLogium Technology has started mass production of its lithium-ceramic battery cells in Taiwan, achieving 381 watt-hours per kilogram. The company is building a €5.2 billion gigafactory in Dunkirk, France, with production expected to begin in 2028. ProLogium aims to list shares on Nasdaq under ticker PRLG via a SPAC merger valued at $3.8 billion. The company has partnerships with Mercedes-Benz and Rimac, and its technology promises higher energy density and improved safety for electric vehicles

ProLogium and Nasdaq-listed SPAC TDAC said they secured commitments for a $50 million primary capital investment from existing ProLogium shareholders at a pre-money valuation of about $3.8 billion to support their proposed business combination. Proceeds are earmarked for scaling next-generation lithium ceramic batteries and building a Dunkirk, France gigafactory, alongside a French subsidy package up to €1.375 billion.

Innovent Biologics (HKEX: 01801) presented Phase 1 data for IBI3001, a first-in-class EGFR/B7H3 bispecific ADC, at the 2026 ESMO Congress. The study showed manageable safety and encouraging efficacy across multiple solid tumors, including NSCLC, pancreatic cancer, and SCLC. The overall ORR was 30.2%, and the DCR was 88.7%. IBI3001 is advancing to Phase 1b dose-optimization studies.

Amgen's Imdelltra combined with AstraZeneca's Imfinzi showed a 58% reduction in death risk for extensive-stage small cell lung cancer patients, increasing median survival to 21.1 months. The study, presented at the European Society for Medical Oncology Congress, suggests potential for Imdelltra as a first-line maintenance therapy. Imdelltra reported $288M in Q2 2023 sales and $627M in 2025 global sales.

Apple's iPhone Duo preorders sold out quickly, with resellers charging up to 4x the retail price. The delay is due to manufacturing issues, particularly with the hinge, which has a low yield rate. Apple's own website shows a shipping date of January 2027. Analysts project 6 million units sold globally in 2026, but production challenges may hinder meeting demand.